78D.F ALZINOVA AB
- Market cap
- EUR 31.6K
- P/E
- -
- P/B
- 0.01x
- ROE
- -14.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 78D.F undervalued?
Graham numberThe Graham number of ALZINOVA AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ALZINOVA AB fundamental analysis
No fundamental analysis for ALZINOVA AB yet.
ALZINOVA AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ALZINOVA AB
Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. The company's lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b clinical trial. It also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzhe…
Full company profileALZINOVA AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ALZINOVA AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 17.3M | 16.6M | 19.6M | 16.8M | 26.6M | 6.20M |
| Operating Income | -7.52M | -13.1M | -16.5M | -20.4M | -25.6M | -20.7M |
| EBITDA | - | -13.1M | -16.4M | -20.3M | -25.3M | -20.6M |
| Net Income | -7.55M | -13.1M | -16.5M | -20.6M | -26.3M | -22.9M |
| EPS | -0.35 | -0.33 | -0.30 | -0.23 | -0.25 | -0.11 |
| Balance Sheet | ||||||
| Total Assets | 91.7M | 112M | 123M | 133M | 143M | 164M |
| Total Liabilities | 3.22M | 6.09M | 9.33M | 9.40M | 21.5M | 7.60M |
| Shareholders' Equity | 88.5M | 106M | 114M | 124M | 122M | 156M |
| Cash & Short-term Investments | 28.8M | 32.0M | 22.0M | 15.5M | 319K | 13.3M |
| Cash Flow | ||||||
| Operating Cash Flow | -9.82M | -10.3M | -15.2M | -20.3M | -13.0M | -49.0M |
| Capital Expenditure | 17.3M | 16.6M | 19.6M | 16.8M | 26.6M | 16.0M |
| Free Cash Flow | -27.1M | -26.9M | -34.8M | -37.0M | -39.6M | -65.0M |
| Ratios | ||||||
| ROE | -8.5% | -12.4% | -14.5% | -16.6% | -21.5% | -14.7% |
| ROA | -8.2% | -11.7% | -13.4% | -15.4% | -18.3% | -14.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
ALZINOVA AB dividends
ALZINOVA AB has not paid dividends in the last 5 fiscal years.
Who owns ALZINOVA AB
- Insiders 15.18%
- Institutions 9.81%
- Public & others 75.01%
- Shares outstanding 316M
- Free float 183M
ALZINOVA AB company profile
- Company name
- ALZINOVA AB
- Ticker
- 78D.F
- ISIN
- SE0007413455
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Fiscal year end
- December
- Address
- GoCo House, Mölndal, Sweden, 431 53
- Phone
- 46 7 08 46 79 75
- Website
- alzinova.com
About ALZINOVA AB
Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. The company's lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b clinical trial. It also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. It has a research collaboration with Amsterdam University Medical Center to develop a blood based test that measures naturally occurring antibodies against toxic amyloid ß oligomers. Alzinova AB (publ) was incorporated in 2011 and is based in Mölndal, Sweden.
ALZINOVA AB management
4- Dr. Tord Labuda M.Sc., Ph.D.Chief Executive Officer
- Mr. Erik KullgrenChief Financial Officer
- Dr. Anders Sandberg Ph.D.Chief Scientific Officer · born 1972
- Mr. Sebastian HanssonBusiness Development Director